Review
Nature Reviews Drug Discovery 5, 997-1014 (December 2006) | doi:10.1038/nrd2154
There is a Corrigendum (1 March 2007) associated with this article.
Mining the Wnt pathway for cancer therapeutics
Nick Barker1 & Hans Clevers1 About the authors
Abstract
Aberrant activation of the Wnt pathway is implicated in driving the formation of various human cancers, particularly those of the digestive tract. Inhibition of aberrant Wnt pathway activity in cancer cell lines efficiently blocks their growth, highlighting the great potential of therapeutics designed to achieve this in cancer patients. Here we provide an overview of the promise and pitfalls of current drug development strategies striving to inhibit the Wnt pathway and present new opportunities for therapeutic intervention.
- View At a Glance
Author affiliations
- Hubrecht laboratory, Netherlands Institute for Developmental Biology, Uppsalalaan 8 3584CT, Utrecht, The Netherlands.
Correspondence to: Nick Barker1 Email: nbarker@niob.knaw.nl
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Shutting down Wnt signal?activated cancerNature Genetics News and Views (01 Apr 2004)
It takes more than two to tango: Dishevelled polymerization and Wnt signalingNature Structural & Molecular Biology News and Views (01 Jun 2007)
RESEARCH
Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancerOncogene Scientific Correspondence
See all 36 matches for Research
